Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate

Phase 1 unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva’s unique, single-shot vaccine candidate

These results strongly support further development acceleration

VLA1553 was generally safe in all dose groups

  • Well-tolerated in the low and medium dose. (Superior safety profile, including viremia, compared to the high dose group)
  • Excellent local tolerability

Excellent immunogenicity profile in all dose groups after a single vaccination

  • 100% Seroconversion1 achieved at Day 14 after a single vaccination in all dose groups
  • Sustained at 100% after six months

Saint Herblain (France), May 22, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced further positive Phase 1 results for its chikungunya vaccine candidate, VLA1553.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)